All Big Pharma articles – Page 11
-
NewsStandout breast cancer trial outcomes for Roche small molecule therapy
The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.
-
NewsAbbVie agrees $1.4 billion Alzheimer's acquisition
The deal will help AbbVie to strengthen its neuroscience pipeline, including supporting development of next-generation therapies for delivery into the central nervous system.
-
NewsACG 2024: J&J data reveals new Crohn's treatment option
More patients given subcutaneous induction and maintenance treatment with Johnson & Johnson’s biologic obtained clinical remission at 48 weeks, compared to placebo, Phase III data showed.
-
ArticleDeveloping donanemab - balancing cost versus benefit
This article summarises recent regulatory developments surrounding the Alzheimer’s treatment donanemab and considers the future therapeutic market for this disease.
-
NewsEli Lilly secures MHRA authorisation for Alzheimer's treatment
Authorisation in Great Britain means eligible Alzheimer's patients can access the treatment, which is part of a new class of amyloid targeting therapies.
-
NewsImmunotherapy treatment enhances lymphoma survival, landmark study shows
The Phase III findings give evidence for the immunotherapy treatment regimen to become standard of care for advanced Hodgkin lymphoma.
-
NewsSanofi collaboration to advance innovative radioligand therapies
The new partnership between Sanofi and Orano Med, delivered via a new entity valued at nearly $2 billion, will focus on progressing lead-212 based targeted alpha therapies for oncology indications.
-
NewsHaemophilia treatment with new delivery method approved
The US FDA has authorised the first treatment for haemophilia A or B that is administered via a pre-filled pen or syringe.
-
ArticleCPHI Milan 2024: everything you need to know
CPHI Milan takes place in October, covering a wide range of topics from packaging and drug delivery to integrated pharma.
-
NewsImproving packaging integrity of pharmaceutical borosilicate glass vials
The study offers promising data on strengthening borosilicate medical glass vials using ion-exchange, especially as there is limited research in this area.
-
ArticleEuropean Pharmaceutical Review Issue 4 2024
European Pharmaceutical Review Issue 4 includes articles on regulation, bioproduction, environmental monitoring, packaging and drug delivery.
-
NewsPharmaLab Congress 2024 - what’s new for the third year in Düsseldorf/Neuss
Find out what is on offer for pharma professionals working in analytical development and microbiology QC at the 12th PharmaLab Congress being held in Germany in 2024.
-
ReportPharma Horizons: Biologics
European Pharmaceutical Review’s latest Pharma Horizons report provides insight on key developments in pharmaceutical biologics for drug development, pharmaceutical manufacturing and quality control.
-
NewsNew collaboration to boost access to innovative microbiome therapies
The new agreement, focused on improving regulation and drug development within the microbiome therapeutic sector, will harness cross-sector cooperation to ensure these medicines become available to more patients.
-
NewsSepsis: addressing unmet needs for a global priority
Limited funding and a lack of drugs targeting the root cause of sepsis are some of the current obstacles when addressing the disease burden, GlobalData says.
-
ArticleEnzyme replacement therapy: improving outcomes in rare disease
In this article, Dr Alaa Hamed, Global Head of Medical Affairs for Rare Disease at Sanofi, shares why the company’s enzyme replacement therapy Xenpozyme® (olipudase alfa) has promise for the rare genetic disease acid sphingomyelinase deficiency (ASMD).
-
WhitepapereBook: Cut through complexity in drug development ebook
How you can cut through complexity, gain speed and get your drug to the patient as soon as possible.
-
ArticleAdvancing NOX inhibitors for treating fibrotic diseases and cancer
This article explores the benefit of NOX inhibitors for fibrotic diseases and cancers and highlights the potential of Calliditas Therapeutics’ drug setanaxib, including its application in wider related indications.
-
NewsNew WHO guidance to support manufacturers to reduce AMR risk
The recommendations offered in the guidance is applicable across different areas of manufacturing, from active pharmaceutical ingredients (APIs), through to formulation and packaging.
-
NewsInnovative pharma-government partnership to enhance UK clinical trials
The first-of-a-kind investment supports the UK government’s objectives to boost clinical trials, improve patient access to novel treatments and increase competitiveness in life sciences.